TSE:BHC Bausch Health Companies (BHC) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free BHC Stock Alerts C$11.68 +0.10 (+0.86%) (As of 09:45 AM ET) Add Compare Share Share Today's RangeC$11.55▼C$11.6850-Day RangeC$11.40▼C$14.3552-Week RangeC$7.56▼C$15.43Volume9,655 shsAverage Volume355,080 shsMarket CapitalizationC$4.27 billionP/E RatioN/ADividend Yield0.76%Price TargetC$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Get Bausch Health Companies alerts: Email Address Bausch Health Companies MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside22.3% DownsideC$9.00 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.12 out of 5 stars 1.0 Analyst's Opinion Consensus RatingBausch Health Companies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBausch Health Companies has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for BHC. Previous Next 0.0 Dividend Strength Dividend YieldBausch Health Companies has a dividend yield of 0.76%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthBausch Health Companies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BHC. Previous Next 0.6 News and Social Media Coverage Search Interest40 people have searched for BHC on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bausch Health Companies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.18% of the stock of Bausch Health Companies is held by insiders.Percentage Held by Institutions81.00% of the stock of Bausch Health Companies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Bausch Health Companies is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bausch Health Companies is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioBausch Health Companies has a PEG Ratio of 0.21. PEG Ratios below 1 indicate that a company could be undervalued. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About Bausch Health Companies Stock (TSE:BHC)Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Read More BHC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BHC Stock News HeadlinesApril 11, 2024 | finanznachrichten.deBausch Health Companies Inc.: Bausch Health to Announce First-Quarter 2024 Results on May 2April 11, 2024 | seekingalpha.comBausch Health seesaws after appeals court affirms ruling in Norwich patent caseApril 23, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.April 11, 2024 | msn.comBausch Health pares gain after appeals court affirms ruling in Norwich patent caseApril 11, 2024 | finance.yahoo.comCourt of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029April 11, 2024 | finanznachrichten.deBausch Health Companies Inc.: Acne Vulgaris Treatment PrARAZLO Now Available to Patients Through British Columbia PharmaCare Public Drug PlanApril 8, 2024 | nasdaq.comTSX Recovers After Early Setback, Ends Slightly DownApril 5, 2024 | theglobeandmail.comBausch Health Companies: Top 10 Undervalued Growth Stocks on TSX (BHC)April 23, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”April 3, 2024 | finance.yahoo.com/C O R R E C T I O N from Source -- Canadian Investment Regulatory Organization (CIRO) - Halts/Resumptions/April 1, 2024 | finance.yahoo.comBreakeven Is Near for Bausch Health Companies Inc. (NYSE:BHC)March 28, 2024 | finance.yahoo.comGlobal Immunoprecipitation Testing Market Industry Trends & 10 Year Growth Forecasts 2019-2029March 13, 2024 | seekingalpha.comSTAAR Surgical Company: Potential Buy After Long-Term Valuation DowngradeMarch 1, 2024 | ca.finance.yahoo.comBHC Mar 2024 8.500 callMarch 1, 2024 | finanznachrichten.deBausch Health Companies Inc.: Bausch Health Companies to Present at Cowen Annual Health Care ConferenceFebruary 24, 2024 | msn.comBausch Health Companies (BHC) Price Target Increased by 5.99% to 6.99February 24, 2024 | finance.yahoo.comBausch + Lomb Corporation (NYSE:BLCO) Yearly Results: Here's What Analysts Are Forecasting For This YearFebruary 23, 2024 | markets.businessinsider.comRBC Capital Maintains Sector Perform Rating for Bausch Health Companies: Here's What You Need To KnowFebruary 23, 2024 | markets.businessinsider.comBausch Health Companies: Sell Rating Justified by Modest Growth Outlook and Persistent UncertaintiesFebruary 23, 2024 | finance.yahoo.comBausch Health Companies Inc. (NYSE:BHC) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | benzinga.comLooking At Bausch Health Companies's Recent Unusual Options ActivityFebruary 22, 2024 | finanznachrichten.deBausch Health Companies Inc.: Bausch Health Announces Fourth-Quarter and Full-Year 2023 ResultsFebruary 22, 2024 | msn.comBausch Health Companies beats top-line and bottom-line estimates; initiates FY24 outlookFebruary 22, 2024 | finance.yahoo.comBausch Health Announces Fourth-Quarter and Full-Year 2023 ResultsFebruary 22, 2024 | finance.yahoo.comBausch Health Companies Inc. Reports Revenue Growth Amidst Net Losses in Q4 and Full-Year 2023February 22, 2024 | finance.yahoo.comBausch Health (BHC) Surpasses Q4 Earnings and Revenue EstimatesFebruary 19, 2024 | finance.yahoo.comInsights Into Bausch (BHC) Q4: Wall Street Projections for Key MetricsSee More Headlines Receive BHC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/23/2024Next Earnings (Confirmed)5/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:BHC CUSIPN/A CIKN/A Webwww.valeant.com Phone514-744-6792FaxN/AEmployees20,270Year FoundedN/APrice Target and Rating Average Stock Price TargetC$9.00 High Stock Price TargetC$9.00 Low Stock Price TargetC$9.00 Potential Upside/Downside-22.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)C($2.20) Trailing P/E RatioN/A Forward P/E Ratio2.34 P/E Growth0.21Net IncomeC$-592,000,000.00 Net Margins-6.76% Pretax MarginN/A Return on Equity-686.52% Return on Assets3.82% Debt Debt-to-Equity Ratio7,583.76 Current Ratio1.30 Quick Ratio0.58 Sales & Book Value Annual SalesC$8.76 billion Price / Sales0.48 Cash FlowC$1.49 per share Price / Cash Flow7.76 Book ValueC($2.80) per share Price / Book-4.14Miscellaneous Outstanding Shares365,410,000Free FloatN/AMarket CapC$4.23 billion OptionableNot Optionable Beta0.83 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Thomas J. Appio (Age 62)CEO & Director Comp: $3.79MMr. John S. Barresi (Age 51)Senior VP, Controller, Chief Accounting Officer & Interim CFO Comp: $1.1MMs. Seana Carson (Age 51)Executive VP & General Counsel Comp: $1.2MMr. Mirza DautbegovicSenior VP & COOMr. Josh CoyleSenior Vice President of Sales & SalixMs. Kathleen FitzpatrickSenior VP & Chief HR OfficerDr. Tage Ramakrishna M.D. (Age 50)Chief Medical Officer and President of R&D Mr. Jeff HartnessExecutive VP of Market Access, Commercial Operations, Neurology, Generics & Government AffairsDr. Graham JacksonSenior VP & Chief Quality OfficerMr. Cees HeimanSenior Vice President of Europe & CanadaMore ExecutivesKey CompetitorsAphriaTSE:APHATilray BrandsTSE:TLRYCronos GroupTSE:CRONValeant Pharmaceuticals InternationalTSE:VRXBELLUS HealthTSE:BLUView All Competitors BHC Stock Analysis - Frequently Asked Questions Should I buy or sell Bausch Health Companies stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares. View BHC analyst ratings or view top-rated stocks. What is Bausch Health Companies' stock price target for 2024? 1 Wall Street analysts have issued 12 month target prices for Bausch Health Companies' shares. Their BHC share price targets range from C$9.00 to C$9.00. On average, they predict the company's share price to reach C$9.00 in the next year. This suggests that the stock has a possible downside of 22.3%. View analysts price targets for BHC or view top-rated stocks among Wall Street analysts. How have BHC shares performed in 2024? Bausch Health Companies' stock was trading at C$10.63 on January 1st, 2024. Since then, BHC shares have increased by 8.9% and is now trading at C$11.58. View the best growth stocks for 2024 here. When is Bausch Health Companies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our BHC earnings forecast. How were Bausch Health Companies' earnings last quarter? Bausch Health Companies Inc. (TSE:BHC) posted its earnings results on Thursday, February, 22nd. The company reported $1.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.36 by $0.19. The company earned $3.28 billion during the quarter, compared to analysts' expectations of $3.05 billion. Bausch Health Companies had a negative trailing twelve-month return on equity of 686.52% and a negative net margin of 6.76%. What other stocks do shareholders of Bausch Health Companies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Chesapeake Energy (CHKAQ), Enbridge (ENB), Aurora Cannabis (ACB), Manulife Financial (MFC), BlackBerry (BB), Bank of Nova Scotia (BNS), Toronto-Dominion Bank (TD), Nutrien (NTR), Suncor Energy (SU) and ARC Resources (ARX). How do I buy shares of Bausch Health Companies? Shares of BHC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:BHC) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch Health Companies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
